The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients

Journal of Human Genetics

Volumn 60, Issue 5, 2015, Pages 273-276

  Tavira, Beatriz ^a   Gómez, Juan ^a   Díaz Corte, Carmen ^a,b,c   Coronel, Diego ^a   Lopez Larrea, Carlos ^a,c   Suarez, Beatriz ^d   Coto, Eliecer ^a,b,c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c Instituto Carlos IIIFEDER   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A5; DIGOXIN; DNA; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; ABCB1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CAUCASIAN; EPITHELIUM CELL; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HOMOZYGOTE; HUMAN; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; GENETIC ASSOCIATION STUDY; GENETICS; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; FEMALE; GENETIC ASSOCIATION STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929884655     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2015.12     Document Type: Article

References (23)

1. MacPhee I. A. M., Fredericks S., Maha M., Moreton M., Carter N. D., Johnston A., et al. Tacrolimus pharmacogenetics: the CYP3A5∗1 allele predicts low dose-normalized tacrolimus blood concentrations in Whites and South Asians. Transplantation 79, 499-502 (2005
2. Thervet E., Anglicheau D., King B., Schlageter M. H., Cassinat B., Beaune P., et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76, 1233-1235 (2003
3. Tsuchiya N., Satoh S., Tada H., Li Z., Ohyama C., Sato K., et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78, 1182-1187 (2004
4. Dai Y., Hebert M. F., Isoherranen N., Davis C. L., Marsh C., Shen D. D., et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. 34, 836-847 (2006
5. Tavira B., Coto E., Díaz-Corte C., Ortega F., Arias M., Torres A., et al. Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin. Chem. Lab. Med. 49, 825-833 (2011
6. Anglicheau D., Verstuyft C., Laurent-Puig P., Becquemont L., Schlageter M. H., Cassinat B., et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14, 1889-1896 (2003
7. Zhang X., Liu Z. H., Zheng J. M., Chen Z. H., Tang Z., Chen J. S., et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin. Transplant. 19, 638-643 (2005
8. Mai I., Perloff E. S., Bauer S., Goldammer M., Johne A., Filler G., et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br. J. Clin. Pharmacol. 58, 548-553 (2004
9. Kurzawski M., Dabrowska J., Dziewanowski K., Domański L., Perużyńska M. & Droździk M. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics 15, 179-188 (2014
10. Woillard J. B., Rerolle J. P., Picard N., Rousseau A., Guillaudeau A., Munteanu E., et al. P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin. Pharmacol. Ther. 88, 95-100 (2010
11. Naesens M., Lerut E., De Jonge H., Van Damme B., Vanrenterghem Y. & Kuypers D. R. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J. Am. Soc. Nephrol. 20, 2468-2480 (2009
12. De Meyer M., Haufroid V., Elens L., Fusaro F., Patrono D., De Pauw L., et al. Donor age and ABCB1 1199G4A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. J. Surg. Res. 178, 988-995 (2012
13. Moore J., McKnight A. J., Döhler B., Simmonds M. J., Courtney A. E., Brand O. J., et al. ABCB1 variant associates with increased risk for kidney allograft failure. J. Am. Soc. Nephrol. 23, 1891-1899 (2012
14. Glowacki F., Lionet A., Buob D., Labalette M., Allorge D., Provôt F., et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol. Dial. Transplant. 26, 3046-3050 (2011
15. Tavira B., Coto E., Diaz-Corte C., Alvarez V., López-Larrea C. & Ortega F. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renaltransplanted patients. Pharmacogenet. Genomics 23, 445-448 (2013
16. Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N. & Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130, 461-470 (1999
17. Pöge U., Gerhardt T., Palmedo H., Klehr H. U., Sauerbruch T. & Woitas R. P. MDRD equations for estimation of GFR in renal transplant recipients. Am. J. Transplant. 5, 1306-1311 (2005
18. Joosten S. A., Sijpkens Y. W., van Kooten C. & Paul L. C. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int. 68, 1-13 (2005
19. Dessilly G., Elens L., Panin N., Capron A., Decottignies A., Demoulin J. B., et al. ABCB1 1199G4A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS ONE 9, e91555 (2014
20. Hoffmeyer S., Burk O., von Richter O., Arnold H. P., Brockmöller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000
21. Capron A., Mourad M., De Meyer M., De Pauw L., Eddour D. C., Latinne D., et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells in the early phase after renal transplantation. Pharmacogenomics 11, 703-714 (2010
22. Crettol S., Venetz J. P., Fontana M., Aubert J. D., Ansermot N., Fathi M., et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics 18, 307-315 (2008
23. Hauser I. A., Schaeffeler E., Gauer S., Scheuermann E. H., Wegner B., Gossmann J., et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16, 1501-1511 (2005